| Literature DB >> 30580797 |
Alberto Leguina-Ruzzi1, Rina Ortiz2, Victoria Velarde3.
Abstract
BACKGROUND: Type 2 diabetes (T2D) can go undiagnosed for years, leading to a stage where produces complications such as delayed skin wound healing. Animal models have been developed in the last decades to study the pathological progression in this disease. Streptozotocin (STZ), that has a selective pharmacological toxicity toward pancreatic β cells, in addition to high fat diet has been widely used to induce diabetes however no evidence has shown its effects on the skin integrity.Entities:
Keywords: Diabetes; Epithelial integrity; Lipid mediators; Skin damage; Streptozotocin
Mesh:
Substances:
Year: 2018 PMID: 30580797 PMCID: PMC6306302 DOI: 10.1016/j.bj.2018.08.005
Source DB: PubMed Journal: Biomed J ISSN: 2319-4170 Impact factor: 4.910
Fig. 1Diabetes induced by STZ-HF diet generates several skin alterations on mice. (A) Weekly weight measurements in non-sedated animals for 5 weeks, (B) weekly basal glucose levels in non-sedated animals after 6 h starving for 5 weeks, (C) basal blood triglycerides and (D) blood insulin levels in non-sedated animals after 6 h starving at 5th week of treatment. (E) Ex vivo TEER and (F) TBARS in skin from animals after 5 weeks of treatment. (G) Representative images of the animals after the protocol and microphotographs of skin MT stains at 20x magnification. (H) Representative western blots and densitometric quantification of adhesion proteins relative to total β-actin. Data expressed as mean ± SEM, n = 6 per group *p < 0.05 ** or ##p < 0.01, ***p < 0.001, One or 2-Way ANOVA, Tukey's post hoc test.
Lipidomics analysis of the skin.
| (pg/mg tissue) | Control | High Fat | High Fat + STZ |
|---|---|---|---|
| AA | 10,380 ± 210 | 8730 ± 150 | 9650 ± 140 |
| DHA | 22,980 ± 660 | 19,370 ± 360 | 10,130 ± 180* |
| EPA | 1410 ± 30 | 1380 ± 20 | 660 ± 10* |
| 12-HHT | 15.22 ± 6.1 | 6.73 ± 2.3 | 4.81 ± 1.2* |
| LTB4 | 0.07 ± 0.01 | 0.05 ± 0.02 | 0.06 ± 0.02 |
| LTC4 | 2.11 ± 0.9 | 0.38 ± 0.1** | 0.41 ± 0.1* |
| PD1 | 19.09 ± 3.2 | 13.29 ± 3.1 | 3.67 ± 1.1** |
| TXB2 | 2.85 ± 1.2 | 1.03 ± 0.2* | 0.88 ± 0.1* |
| PGD2 | 0.05 ± 0.01 | 0.03 ± 0.01 | 0.24 ± 0.06** |
| PGE2 | 51.68 ± 11.5 | 82.62 ± 26.2 | 104.0 ± 13.2* |
| 6-keto-PGF1α | 5.51 ± 1 | 3.42 ± 1 | 2.65 ± 0.4* |
| PGF2α | 2.42 ± 0.5 | 3.87 ± 2.3 | 4.59 ± 1.3 |
| 5-HEPE | 0.13 ± 0.07 | 0.11 ± 0.07 | 0.12 ± 0.1 |
| 8-HEPE | 0.47 ± 0.1 | 0.53 ± 0.2 | 0.3 ± 0.1 |
| 12-HEPE | 0.92 ± 0.2 | 1 ± 0.3 | 1.43 ± 0.3 |
| 15-HEPE | 0.76 ± 0.3 | 0.6 ± 0.1 | 0.76 ± 0.2 |
| 18-HEPE | 0.16 ± 0.02 | 0.19 ± 0.06 | 0.4 ± 0.2 |
| 9-HODE | 340 ± 100 | 370 ± 100 | 1040 ± 200** |
| 13-HODE | 60 ± 0.5 | 130 ± 1 | 410 ± 0.7** |
| 5-HEPE | 1.4 ± 0.3 | 1.3 ± 0.2 | 1.5 ± 0.5 |
| 8-HEPE | 10 ± 0.3 | 10 ± 0.4 | 4.2 ± 1 |
| 11-HEPE | 1 ± 0.4 | 2 ± 0.9 | 2 ± 0.6 |
| 12-HEPE | 60 ± 10 | 40 ± 20 | 80 ± 20 |
| 15-HEPE | 20 ± 7 | 20 ± 8 | 20 ± 9 |
| 7-HDoHE | 1.81 ± 0.12 | 3.74 ± 0.85* | 3.34 ± 0.5* |
| 14-HDoHE | 0.02 ± 0.01 | 0.01 ± 0.002 | 0.02 ± 0.005 |
| 17-HDoHE | 0.05 ± 0.02 | 0.04 ± 0.01 | 0.03 ± 0.01 |
| 5-KETE | 1.57 ± 0.42 | 0.48 ± 0.09** | 0.25 ± 0.15** |
| 12-KETE | 0.54 ± 0.25 | 0.23 ± 0.12 | 0.21 ± 0.06* |
| 5, 6 EET | 0.09 ± 0.04 | 0.04 ± 0.02 | 0.06 ± 0.03 |
| 8, 9 EET | 0.33 ± 0.08 | 0.11 ± 0.03 | 0.03 ± 0.01* |
Lipid mediator levels in skin after 5 weeks of controlled diet with or without STZ (average ± SEM), n = 6 per group, ∗p < 0.05, ∗∗p < 0.01 non parametric one-way ANOVA with Tukey's post hoc test. Abbreviations: AA: Arachidonic acid; LTB4; Leukotriene B4; HEPE: Hydroxyeicosatetraenoic acid;